CDMO News and Research

RSS

LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

From LGM Pharma 13 Mar 2024

BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers.

From BioCina Pty Ltd. 29 Feb 2024

Marking a vital milestone for Vertex and Charles River

Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease

From Charles River 9 Jan 2024

Cellular Origins, a TTP Company, establishes Advisory Board of global industry leaders

Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives.

From Cellular Origins 9 Jan 2024

Gene Therapy Contract Development and Manufacturing: Challenges and Future Perspectives

In this interview conducted at the Cell and Gene Therapy Summit Tour London, we speak to Ramin Baghirzade, Global Head of Commercial at Charles River for Gene Therapy, about the Gene Therapy CDMO solutions that Charles River Laboratories offers and more.

From Charles River Laboratories, Inc. 18 Jul 2023

Vernal Biosciences Announces Partnership With REPROCELL

Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications.

From REPROCELL 11 Jul 2023

Cell and gene therapy CDMO Andelyn Biosciences celebrates over 20 years of leadership and innovation with opening of new 180,000 square foot manufacturing headquarters

Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, today formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio.

From Andelyn Biosciences 23 Jun 2023

Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.

From Charles River Laboratories, Inc. 13 Jun 2023

LGM Pharma Reports Strong Revenues in First Year of CDMO Operations Along With Continued Growth in Its API Sourcing Business

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today reported strong growth in 2022 in both its long-established Active Pharmaceutical Ingredient (API) division and its new contract development and manufacturing (CDMO) division.

From LGM Pharma 16 Mar 2023

Product development and drug delivery at Seda

In this interview, NewsMedical speaks with Shanoo about her career progression and role in Seda Pharmaceutical regarding product development and drug delivery. She also outlines some of the services that Seda offers.

From Seda Pharmaceutical Development Services 1 Mar 2023

Lonza delivers strong 2022 performance with 15.1% CER sales growth and 32.1% CORE EBITDA margin

Lonza has reported sales of CHF 6.2 billion, sales growth of 15.0% AER (15.1% CER), and CHF 2.0 billion CORE EBITDA, resulting in a margin of 32.1%. These robust financial results are driven by strong underlying business performance and a COVID-related sales peak in 2022 which enhanced both sales and margin.

From Lonza 7 Feb 2023

Oncodesign Services looks to the future

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.

From Oncodesign Services 3 Feb 2023

Fujifilm Europe supports World Cancer Day

Fujifilm Europe has announced its partnership with World Cancer Day, an initiative led by the Union for International Cancer Control (UICC), the largest and oldest international cancer organisation dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.

From FUJIFILM Corporation 23 Jan 2023

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

In this interview, Niall Dinwoodie, Executive Director for Gene Therapy for Charles River in Europe discusses the opening of their new HQ Plasmid Center of Excellence at Alderley Park.

From Charles River Laboratories, Inc. 4 Nov 2022

Celebrating the Alderley Park Grand Opening

HQ Plasmid Center of Excellence based at UK life science hotspot now open for business.

From Charles River Laboratories, Inc. 24 Oct 2022

Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue

Monon Bioventures LLC has received a one-year, $398,314 Phase I Small Business Innovation Research, or SBIR grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy.

22 Sep 2022

Evonik now offers enteric protected ready to fill capsules EUDRACAP® in IPEC-GMP quality

Evonik’s EUDRACAP® enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP® enteric are functional, ready-to-fill capsules that help pharmaceutical companies bring complex oral drug products to market faster.

From Evonik Health Care 14 Jul 2022

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

DZNE and Intravacc B.V., a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines, have been awarded a funding of € 2.5 million from the European Union (EIC Transition Grant) to further develop a prototype ALS vaccine, including process development, scale-up, and toxicology study.

6 Jul 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

VectorBuilder to expand with $500 million ‘Gene Delivery Research and Manufacturing Campus

VectorBuilder Inc. has announced the construction of a new R&D and manufacturing center in Guangzhou, China.

From VectorBuilder 12 Apr 2022